Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain

Vicente Estrada(Instituto de Salud Carlos III), Itziar Oyagüez(Pharmacoeconomics and Health Outcomes Research Iberia (Spain)), Antonio Arjona Castro(University of Almería), J.A. Peña(Hospital Clínico San Carlos), Miguel Górgolas(Hospital Universitario Fundación Jiménez Díaz), Elena Tortajada(Hospital Universitario Fundación Jiménez Díaz), María Presa(Pharmacoeconomics and Health Outcomes Research Iberia (Spain))
PharmacoEconomics - Open
February 5, 2022
10.1007/s41669-022-00322-w
Cited by 16

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Diverse values of nature for sustainability
|Nature|2023|656
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
|The Lancet|2006|343